CRISPR Therapeutics

Historical price data

CRISPR Therapeutics is a pioneering biopharmaceutical company dedicated to discovering, developing, and commercializing curative gene-editing treatments. Founded by CRISPR gene-editing pioneers, the company leverages its proprietary CRISPR/Cas9 platform to create a diverse pipeline targeting hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo diseases. Its landmark achievement is the approval of CASGEVY, the world's first CRISPR/Cas9 gene-edited therapy, marking a new era in medicine and validating its platform's potential. The company collaborates with Vertex Pharmaceuticals and Bayer to accelerate development and commercialization across multiple therapeutic areas.

Proprietary CRISPR/Cas9 gene-editing platform enabling both ex vivo (cell therapy) and in vivo (direct administration) therapeutic approaches, with a focus on allogeneic (off-the-shelf) cell therapies.

8 drugs in pipeline

Total raised: $421M

Main competitors include bluebird bio in hemoglobinopathies, and Allogene Therapeutics, Caribou Biosciences, and Intellia Therapeutics in the broader gene-editing and allogeneic cell therapy space. CRISPR Therapeutics differentiates through its first-mover approval, integrated platform spanning ex vivo and in vivo approaches, and strong strategic partnerships.